Posted by Michael Wonder on 20 Jul 2025
Amivantamab in combination with lazertinib for the first-line treatment of patients with advanced EGFR mutation positive non-small cell lung cancer
4 July 2025 - The Department of Health and Social Care has NICE to produce guidance on the use of amivantamab in combination with lazertinib mesylate monohydrate in the NHS in England.
For the time being, the combination of amivantamab and lazertinib mesylate monohydrate should not be used for the first-line treatment of adults with advanced non-small-cell lung cancer whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletion or an exon 21 L858R substitution mutation.
